Loading
Two genes that, when broken in a lung cancer that also has a faulty KRAS gene, predict that immunotherapy will work much less well. In a lung cancer with a normal KRAS gene the same faults appear to make no difference.
STK11 (LKB1) and KEAP1 are among the most frequently inactivated genes in lung adenocarcinoma, at 13 to 18% and 11 to 18% by cohort, rising to 22.1% each among patients selected for PD-(L)1 blockade (cBioPortal). STK11 loss makes a tumour immune-poor, with low PD-L1 and few infiltrating lymphocytes, and was first tied to PD-1 inhibitor resistance in KRAS-mutant disease (Skoulidis 2018); KEAP1 loss frees NRF2 and switches on an antioxidant programme, and was the strongest independent predictor of short survival among 330 KRAS-mutant patients (hazard ratio 1.96, and 3.54 from the start of immunotherapy) (Arbour 2018). The dependence on KRAS status is the part most often forgotten: across 1,261 patients in two cohorts, STK11 and KEAP1 mutations predicted worse progression-free survival (hazard ratios 2.04 and 2.05) and overall survival (2.09 and 2.24) on PD-(L)1 blockade only in KRAS-mutant tumours, with no effect in KRAS wild-type disease, and the immune phenotype differences were similarly confined (Ricciuti 2022). In the randomised setting the picture is weaker still: neither gene changed the benefit of pembrolizumab monotherapy in KEYNOTE-042 nor of pembrolizumab with chemotherapy in KEYNOTE-189 and KEYNOTE-407 (Mok 2023, Garassino 2023).
In plain words · STK11 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
This result is a prediction about how well immunotherapy is likely to work, not a rule about what can be given. It is used alongside the PD-L1 result and the rest of the genetic report when a treatment plan is discussed, and it matters mainly when the cancer also carries a KRAS change.
Written only from the label or guideline text cited on this page. Not medical advice; your own report and the reading your team gives it come first.
A deleterious (truncating, splice-site or known damaging missense) mutation in STK11 or KEAP1 on tumour sequencing, interpreted only together with KRAS status, since the association with immunotherapy outcome is confined to KRAS-mutant tumours.
“STK11 and KEAP1 mutations were associated with significantly worse progression-free and overall survival to immunotherapy uniquely among KRAS-mutant but not KRAS wild-type lung adenocarcinomas”
Ricciuti et al., Journal of Thoracic Oncology 2022No approval uses this readout as a threshold. It is defined by Skoulidis et al., Cancer Discovery 2018: STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma.
It is the positive half of the tumour mutational burden story and it applies only to single-agent immunotherapy, which is the setting fewest patients are treated in.
This is the result that ended tumour mutational burden as a practical selector in lung cancer: in the regimen most patients receive, it selects nobody, and neither do the co-mutations most often quoted as reasons to withhold immunotherapy.
It corrected a widely repeated simplification. An STK11 or KEAP1 mutation is not by itself a reason to expect immunotherapy to fail; it is a reason to expect it in a KRAS-mutant tumour, which is how the result should be read on a report.
One of the most cited trial reports Europe PMC returns for KRAS in Non-small-cell lung cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
It separated the prognostic co-mutation, KEAP1, from the predictive one, STK11, in a disease where the two are often quoted together, and it is the reason KEAP1 status is worth reading off a report even though no treatment depends on it.
Shares STK11 / KEAP1 co-mutations, KEAP1-NRF2 antioxidant pathway, KEAP1, STK11.
Shares Drug resistance (primary and acquired), Comprehensive genomic profiling, Non-small-cell lung cancer and the tag biomarker.
Shares Drug resistance (primary and acquired), Comprehensive genomic profiling, Non-small-cell lung cancer and the tag biomarker.
Shares STK11 / KEAP1 co-mutations, KEAP1, STK11, T-cell exhaustion.
Shares Associations of tissue tumour mutational burden and mutational status with clinical outcomes with pembrolizumab plus chemotherapy versus chemotherapy for metastatic non-small-cell lung cancer, Associations of tissue tumour mutational burden and mutational status with clinical outcomes in KEYNOTE-042, Non-small-cell lung cancer and the tag biomarker.
Shares PD-L1 TPS (tumour proportion score), Non-small-cell lung cancer and the tag biomarker.
Shares PD-L1 TPS (tumour proportion score), Non-small-cell lung cancer and the tag biomarker.
Shares Drug resistance (primary and acquired), Comprehensive genomic profiling and the tag biomarker.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/